Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

Jing Liu, Stephen Blake, Michelle C.R. Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S. O’Donnell, Stacey Allen, Mark J. Smyth, Michele W.L. Teng

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. SIGNIFICANCE: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome.

LanguageEnglish
Pages1382-1399
Number of pages18
JournalCancer Discovery
Volume6
Issue number12
DOIs
Publication statusPublished - 1 Dec 2016
Externally publishedYes

ASJC Scopus subject areas

  • Oncology

Cite this

Liu, J., Blake, S., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., ... Teng, M. W. L. (2016). Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discovery, 6(12), 1382-1399. https://doi.org/10.1158/2159-8290.CD-16-0577
Liu, Jing ; Blake, Stephen ; Yong, Michelle C.R. ; Harjunpää, Heidi ; Ngiow, Shin Foong ; Takeda, Kazuyoshi ; Young, Arabella ; O’Donnell, Jake S. ; Allen, Stacey ; Smyth, Mark J. ; Teng, Michele W.L. / Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. In: Cancer Discovery. 2016 ; Vol. 6, No. 12. pp. 1382-1399.
@article{1afe5b8f49bd4fb88b6291e2fcd5e9e1,
title = "Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease",
abstract = "Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. SIGNIFICANCE: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome.",
author = "Jing Liu and Stephen Blake and Yong, {Michelle C.R.} and Heidi Harjunp{\"a}{\"a} and Ngiow, {Shin Foong} and Kazuyoshi Takeda and Arabella Young and O’Donnell, {Jake S.} and Stacey Allen and Smyth, {Mark J.} and Teng, {Michele W.L.}",
year = "2016",
month = "12",
day = "1",
doi = "10.1158/2159-8290.CD-16-0577",
language = "English",
volume = "6",
pages = "1382--1399",
journal = "Cancer Discovery",
issn = "2159-8274",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

Liu, J, Blake, S, Yong, MCR, Harjunpää, H, Ngiow, SF, Takeda, K, Young, A, O’Donnell, JS, Allen, S, Smyth, MJ & Teng, MWL 2016, 'Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease', Cancer Discovery, vol. 6, no. 12, pp. 1382-1399. https://doi.org/10.1158/2159-8290.CD-16-0577

Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. / Liu, Jing; Blake, Stephen; Yong, Michelle C.R.; Harjunpää, Heidi; Ngiow, Shin Foong; Takeda, Kazuyoshi; Young, Arabella; O’Donnell, Jake S.; Allen, Stacey; Smyth, Mark J.; Teng, Michele W.L.

In: Cancer Discovery, Vol. 6, No. 12, 01.12.2016, p. 1382-1399.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease

AU - Liu, Jing

AU - Blake, Stephen

AU - Yong, Michelle C.R.

AU - Harjunpää, Heidi

AU - Ngiow, Shin Foong

AU - Takeda, Kazuyoshi

AU - Young, Arabella

AU - O’Donnell, Jake S.

AU - Allen, Stacey

AU - Smyth, Mark J.

AU - Teng, Michele W.L.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. SIGNIFICANCE: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome.

AB - Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. SIGNIFICANCE: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8 + T cells immediately prior to and post surgery may provide a predictor of outcome.

UR - http://www.scopus.com/inward/record.url?scp=85007295572&partnerID=8YFLogxK

U2 - 10.1158/2159-8290.CD-16-0577

DO - 10.1158/2159-8290.CD-16-0577

M3 - Article

VL - 6

SP - 1382

EP - 1399

JO - Cancer Discovery

T2 - Cancer Discovery

JF - Cancer Discovery

SN - 2159-8274

IS - 12

ER -